OnKure Therapeutics, Inc. (OKUR) Stock Score, Valuation & Financial Research

OnKure Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for OKUR

OnKure Therapeutics, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 2.43. These figures are a research snapshot, not a buy or sell recommendation.

What OnKure Therapeutics, Inc. does

OnKure, Inc., established in 2011 and based in Boulder, Colorado, operates as a biopharmaceutical company primarily engaged in the creation and advancement of precise therapeutic agents for cancer. A core area of their research centers on developing highly selective inhibitors for histone deacetylases. Their current pipeline features OKI-179, an inhibitor specifically engineered to combat a wide spectrum of malignancies, including both blood-related cancers and solid tumor formations.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

OnKure Therapeutics is a clinical-stage biopharmaceutical company that generates no product revenue. Its business model relies on raising capital through equity offerings and potential future licensing or collaboration agreements to fund the research and development of precision medicines targeting cancer drivers.

Products and services

  • The company is focused on the discovery and development of small molecule precision medicines, including its lead clinical-stage product candidate, OKI-219, which is a PI3K alpha inhibitor.

Customer types

Clinical trial patients and healthcare providers.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) — The company relies on third-party providers for the manufacturing of drug substances and drug products, as well as for the conduct of preclinical and clinical trials. Source

Business strengths to evaluate

  • Proprietary precision medicine discovery platform Source

Business risks and research considerations

  • History of operating losses and expectation of future losses Source
  • Dependence on third-party manufacturers and clinical trial sites Source
  • Need for additional capital to fund operations Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

OKUR financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 2.43
Market capitalization:
98.41M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -58.71M
Free cash flow:
USD -51.87M
Cash:
USD 166.5M
Total debt:
USD 926K
EPS:
USD -3.50

What stands out

  • Free cash flow is USD -51.87M, negative for the stored period.
  • The balance sheet shows USD 166.5M of cash versus USD 926K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 165.58M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for OKUR

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can OKUR fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is OKUR likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for OKUR to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of OKUR's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-12.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research OKUR

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.